Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
Open Access
- 18 June 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (12), 3581-3584
- https://doi.org/10.1038/s41375-021-01324-z
Abstract
No abstract availableFunding Information
- Servier
This publication has 15 references indexed in Scilit:
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesThe Lancet, 2020
- Next-Generation Manufacturing Protocols Enriching TSCMCAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer PatientsFrontiers in Immunology, 2020
- First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.Journal of Clinical Oncology, 2020
- Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell TherapyBlood, 2019
- Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric CancersCancer Discovery, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemiaNature Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaThe New England Journal of Medicine, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013